Trial Profile
Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Conbercept (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Adverse reactions; Therapeutic Use
- 09 Jun 2017 New trial record